EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data

Veronika Lappe, Truc Sophia Dinh, Sebastian Harder, Maria-Sophie Brueckle, Joachim Fessler, Ursula Marschall, Christiane Muth, Ingrid Schubert

Pharmacoepidemiology · 2022

DOI: 10.3390/pharma1010002 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Pharmacoepidemiology, 2022. Verfasst von Veronika Lappe und 7 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Innovation Funds of the German Joint Federal Committee.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

About 10 years ago, several guidelines for the better management of patients with polypharmacy were issued. A central issue is the definition of the target group. The primary aim of this study is therefore to assess the size of the target group, applying the criteria of the German guidelines. A further aim is to describe the frequency of occurrence of medication safety issues for patients of the target group. (2)

Methods

The study is based on administrative data of one large statutory health insurer in Germany (n = 9,012,523). (3)

Results

The criteria of multimorbidity (at least three chronic diseases) and utilization of five or more concurrent drugs over at least 91 days is fulfilled by 14.1% of the insured patients, or almost 1.3 million persons. About 5% of this multimorbid and poly-medicated population fulfilled at least three of out of five additional occasion-related criteria. Medication safety issues occur frequently: treatment prevalence with potentially inadequate medication, QT-drugs, benzodiazepine or Z-drugs and proton pump inhibitors was 30.4%, 28.9%, 11.1% and 52.4%, respectively. (4)

Conclusions

The analysis shows the scope of patients eligible for a structured medication review and demonstrates the relevance for counselling based on the high percentage potentially at risk due to medication therapy safety problems.

Förderung

  • German Innovation Funds of the German Joint Federal Committee

Zitieren

APA

Lappe, V., Dinh, T. S., Harder, S., Brueckle, M., Fessler, J., Marschall, U., Muth, C., & Schubert, I. (2022). Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data. Pharmacoepidemiology. https://doi.org/10.3390/pharma1010002

Vancouver

Lappe V, Dinh TS, Harder S, Brueckle M, Fessler J, Marschall U, et al. Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data. Pharmacoepidemiology. 2022. doi:10.3390/pharma1010002

BibTeX
@article{Lappe2022,
  author = {Lappe, Veronika and Dinh, Truc Sophia and Harder, Sebastian and Brueckle, Maria-Sophie and Fessler, Joachim and Marschall, Ursula and Muth, Christiane and Schubert, Ingrid},
  title = {Multimedication Guidelines: Assessment of the Size of the Target Group for Medication Review and Description of the Frequency of Their Potential Drug Safety Problems with Routine Data},
  journal = {Pharmacoepidemiology},
  year = {2022},
  doi = {10.3390/pharma1010002}
}
Kostenlos starten →